A Phase 3, Randomized, Open-Label Study Of Pf-06821497 (Mevrometostat) In Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (MEVPRO-1)

Nature and Objective:
The MEVPRO-1 study investigates the efficacy of mevrometostat (PF-06821497), an oral inhibitor of EZH2, in combination with enzalutamide, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed following abiraterone acetate treatment. The trial compares this combination to either enzalutamide alone or docetaxel chemotherapy, assessing its impact on radiographic progression-free survival.